Expanded Access Data Confirm Safety, Efficacy of Ruxolitinib in Myelofibrosis

Published: Friday, Dec 16, 2016

Lynda Foltz, MD

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial, a review of data from an expanded access program showed.¹

1. Foltz L, Paulmbo GA, Martino B, et al. Safety and efficacu of ruxolitinib for the final enrollment of JUMP: an open-label, multicenter, single-arm expanded-access study in patients with myelofibrosis. Presented at: 58th ASH Annual Meeting and Exposition; December 2-6, 2016; San Diego, CA. Abstract 3107.

... to read the full story

To Read the Full Story

View Conference Coverage

2019 State of the Science Summit on Genitourinary Cancers in Jacksonville

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

2019 State of the Science Summit on Hematologic Malignancies in Seattle

15th International Conference on Malignant Lymphoma

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies	Jul 30, 2019	1.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?	Jul 31, 2019	1.5